Production (Stage)
Pangenomic Health Inc.
NARA
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 122.29% | 438.85% | -63.27% | -70.45% | -74.30% |
| Gross Profit | -122.29% | -438.85% | 63.27% | 70.45% | 74.30% |
| SG&A Expenses | 52.90% | -72.53% | -41.65% | -74.84% | -74.03% |
| Depreciation & Amortization | -95.65% | -95.65% | -34.78% | 0.00% | 4.55% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.21% | -2.06% | -51.18% | -74.34% | -80.51% |
| Operating Income | -92.21% | 2.06% | 51.18% | 74.34% | 80.51% |
| Income Before Tax | -71.97% | -48.60% | 51.46% | -159.56% | 79.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.97% | -48.60% | 51.46% | -159.56% | 79.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.97% | -48.60% | 51.46% | -159.56% | 79.26% |
| EBIT | -92.21% | 2.06% | 51.18% | 74.34% | 80.51% |
| EBITDA | -95.29% | 1.49% | 51.35% | 74.61% | 80.77% |
| EPS Basic | 50.06% | 43.37% | 84.96% | 7.85% | 80.51% |
| Normalized Basic EPS | 50.10% | 61.61% | 84.55% | 90.50% | 80.52% |
| EPS Diluted | 50.06% | 43.37% | 84.96% | 7.85% | 80.51% |
| Normalized Diluted EPS | 50.10% | 61.61% | 84.55% | 90.50% | 80.52% |
| Average Basic Shares Outstanding | 244.55% | 162.36% | 222.15% | 181.71% | 6.42% |
| Average Diluted Shares Outstanding | 244.55% | 162.36% | 222.15% | 181.71% | 6.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |